BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition.

ABSTRACT: Leukemia is characterized by genetic and epigenetic mutations resulting in selection of cancer cells, which are unable to differentiate. Although genetic alterations are difficult to target, the epigenome is intrinsically dynamic and readily offers new therapeutic strategies. Thus, identifying cancer-specific context-dependent targets and unraveling their biological function may open up new therapeutic perspectives. Here we identify bromodomain-containing protein 9 (BRD9) as a critical target required in acute myeloid leukemia (AML). We show that BRD9 is overexpressed in AML cells including ex vivo primary blasts compared with CD34⁺ cells. By targeting BRD9 expression in AML, we observed an alteration in proliferation and survival, ultimately resulting in the induction of apopto

SUBMITTER: Del Gaudio N 

PROVIDER: S-EPMC6472371 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature